Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
Clinical trial NCT06109207 · UNKNOWN
Trial details
- NCT number
- NCT06109207
- Sponsor
- West China Hospital
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-31
- Primary completion
- 2024-10-31
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.